Zoetis (ZTS) Change in Account Payables (2014 - 2026)
Zoetis' (ZTS) quarterly Change in Account Payables came in at $62.0 million in Q1 2026, up 181.82% year-on-year from $22.0 million in Q1 2025, and down 18.42% on a QoQ basis from $76.0 million in Q4 2025.
Zoetis (ZTS) Change in Account Payables (2014 - 2026) Analysis & Trends
Zoetis (ZTS) has 13 years of Change in Account Payables data on file, last reported at $62.0 million in Q1 2026.
- On a quarterly basis, Change in Account Payables rose 181.82% year-over-year to $62.0 million in Q1 2026; TTM through Mar 2026 was $86.0 million, a 53.57% increase from a year earlier, with the FY2025 full-year figure at $46.0 million, up 48.39% from the prior year.
- Change in Account Payables for Q1 2026 stood at $62.0 million, down from $76.0 million in the prior quarter.
- Over the last five years, Change in Account Payables for ZTS reached as high as $76.0 million in Q4 2025 and fell as low as -$74.0 million in Q3 2023.
- Historically, Change in Account Payables has averaged $7.2 million across 5 years, with a median of $22.0 million in 2023.
- Across the five-year window, Change in Account Payables plunged 365.0% in 2022 and jumped 833.33% in 2025, its largest moves.
- Year by year, Change in Account Payables stood at $30.0 million in 2022, then decreased by 26.67% to $22.0 million in 2023, then rose by 18.18% to $26.0 million in 2024, then jumped by 192.31% to $76.0 million in 2025, then declined by 18.42% to $62.0 million in 2026.
- Per Business Quant data, the three most recent Change in Account Payables figures were $62.0 million in Q1 2026, $76.0 million in Q4 2025, and -$54.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 30.60 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 32.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62.00 Mn |
| Mar 31, 2026 | 62.00 Mn |
| Dec 31, 2025 | 76.00 Mn |
| Dec 31, 2025 | 76.00 Mn |
| Sep 30, 2025 | -54.00 Mn |
| Sep 30, 2025 | -54.00 Mn |
| Jun 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | 2.00 Mn |
| Mar 31, 2025 | 22.00 Mn |
| Mar 31, 2025 | 22.00 Mn |
| Dec 31, 2024 | 26.00 Mn |
| Dec 31, 2024 | 26.00 Mn |
| Sep 30, 2024 | -15.00 Mn |
| Sep 30, 2024 | -15.00 Mn |
| Jun 30, 2024 | 23.00 Mn |
| Jun 30, 2024 | 23.00 Mn |
| Mar 31, 2024 | -3.00 Mn |
| Mar 31, 2024 | -3.00 Mn |
| Dec 31, 2023 | 22.00 Mn |
| Dec 31, 2023 | 22.00 Mn |